 This study reports that patients with psoriasis may have a higher risk of Candida SPP infection and that anti-Illinois 17 antibodies, which are used to treat psoriasis, may increase the incidence of these infections. However, a case series of 16 patients treated with Secukinumab 300 mg for one year did not show an increase in Candida SPP infection, even asymptomatically, and two patients became negative for Candida detection after treatment without additional antifungal therapy. The results suggest that the risk of Candida infection during Secukinumab therapy may be low. This article was authored by Manuela Papini and Yelena Natalini.